EyePoint, Inc. (EYPT)
| Market Cap | 1.12B |
| Revenue (ttm) | 31.37M |
| Net Income (ttm) | -231.96M |
| Shares Out | 83.43M |
| EPS (ttm) | -3.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 471,612 |
| Open | 13.44 |
| Previous Close | 13.60 |
| Day's Range | 13.28 - 13.85 |
| 52-Week Range | 5.30 - 19.11 |
| Beta | 1.91 |
| Analysts | Strong Buy |
| Price Target | 31.80 (+136.08%) |
| Earnings Date | May 1, 2026 |
About EYPT
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet ... [Read more]
Financial Performance
In 2025, EyePoint's revenue was $31.37 million, a decrease of -27.50% compared to the previous year's $43.27 million. Losses were -$231.96 million, 77.2% more than in 2024.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for EYPT stock is "Strong Buy." The 12-month stock price target is $31.8, which is an increase of 136.08% from the latest price.
News
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with seriou...
EyePoint Transcript: RBC Capital Markets Virtual Ophthalmology Conference
DURAVYU is advancing through four phase III trials for wet AMD and DME, with strong safety and efficacy data supporting non-inferiority to EYLEA and significant reduction in treatment burden. Top-line results for LUGANO are expected in August, and the company is well-funded through 2027.
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug
EyePoint filed a lawsuit on Friday accusing rival Ocular Therapeutix of spreading false or misleading information about EyePoint and its lead experimental eye drug.
EyePoint Earnings Call Transcript: Q4 2025
DURAVYU advanced through pivotal Phase III trials in wet AMD and DME, supported by strong safety and efficacy data, robust cash reserves, and expanded commercial readiness. Top-line data for wet AMD is expected in mid-2026, with DME data in 2027.
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
– Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME – – Michael Ca...
EyePoint Transcript: TD Cowen 46th Annual Health Care Conference
Phase III trials for DME and wet AMD are progressing on schedule, with strong safety and efficacy signals and a unique mechanistic profile for DURAVYU. The company anticipates significant market share and expedited regulatory timelines, leveraging operational efficiencies and a differentiated product profile.
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema
– Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets –
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with s...
EyePoint Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with s...
EyePoint Appoints Michael Campbell as Chief Commercial Officer
– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma – – Brings established track record of successful product launches and oversight of ...
EyePoint Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Two pivotal phase III wet AMD trials are fully enrolled, with LUGANO data expected mid-year and DME trials underway. DURAVYU aims for six-month dosing, strong safety, and broad market potential, with robust financials supporting programs into 2027.
EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
WATERTOWN, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with s...
EyePoint Transcript: 44th Annual J.P. Morgan Healthcare Conference
DURAVYU, a sustained-release retinal therapy, is advancing through phase III trials for wet AMD and DME, with top-line data expected mid-year. The product's multi-mechanism action and six-month dosing aim to address unmet needs, supported by strong safety, robust financials, and a scalable manufacturing facility.
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-20...
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with s...
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
– No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU – – On track ...
EyePoint Transcript: Stifel 2025 Healthcare Conference
Phase III trials for wet AMD are fully enrolled with data expected mid-2026, while DME trials will begin dosing in early 2025. Duravyu's multi-MOA sustained-release platform targets major unmet needs, aiming to reduce treatment burden and improve outcomes, supported by strong safety and robust funding.
EyePoint Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Pivotal phase III trials in wet AMD are fully enrolled, with top-line results expected mid next year, while DME phase III trials will begin in Q1. The sustained-release therapy offers a novel multi-mechanism approach, showing strong safety and efficacy, and aims for a first-to-market advantage.
EyePoint Earnings Call Transcript: Q3 2025
DURAVYU's phase III wet AMD trials are fully enrolled with top-line data expected mid-2026, and the DME program is set to begin dosing in Q1 2026. Q3 revenue declined year-over-year due to prior licensing, but a strong cash position supports operations into Q4 2027.
EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments
– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU ™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 –
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025
WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shared details on Tuesday about its pivotal Phase 3 program of Duravyu (vorolanib intravitreal insert) for diabetic macular edema (DME) and began first pat...
EyePoint Announces Pricing of Public Offering
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
EyePoint Announces Proposed Public Offering of Common Stock
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema
– DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 –